Table 2 Health outcomes for full and subpopulations in short and long-term time horizons

Baseline attributes

 Age (IQR; SD)

45.4 (37.2, 53.0; 11.48)

 Proportion CM, %

45.9

–

–

 MMDs (IQR)

14.3 (9.0, 20.3)

9.2 (8.2, 10.1)

20.3 (17.9,2 2.8)

5-year truncated time horizon^a

 Proportion transforming, %

15.2

–

15

 Age at transformation (yrs) (IQR)

49.5 (46.5, 52.6)

–

49.5

 Proportion resolving, %

13.9

 Age at resolution (yrs) (IQR)

52.9 (49.9, 56.0)

52.8

53.0

 Days with migraine, eptinezumab

643

426

899

 Days with migraine, BSC

789

521

1,105

 Years on treatment, eptinezumab

1.6

1.2

1.9

 Years on treatment, BSC

0.4

0.3

0.4

 Proportion TEAE discontinuation, % (timing, yrs) (SD)

4.3 (0.09)

3.7 (0.08)

5.1 (0.11)

 Proportion other-cause discontinuation, % (timing, yrs) (SD)

20.1 (0.20)

16.0 (0.16)

24.9 (0.25)

 Proportion super-responding, %

3.2

3.2

3.2

Lifetime horizon

 Proportion transforming, %

62.8

–

62.8

 Age at transformation (yrs)

50.6

–

50.6

 Proportion resolving, %

73

 Age at resolution (yrs)

54.5

54.4

54.6

 Years with migraine from start of treatment, eptinezumab

14.5

13.3

16.0

 Years with migraine from start of treatment, BSC

16.0

15.7

16.3

 Days with migraine, eptinezumab

2,886

2,198

3,699

 Days with migraine, BSC

3,245

2,437

4,199

 Years on treatment, eptinezumab

3.6

2.7

4.6

 Years on treatment, BSC

0.4

0.3

0.4

 Proportion TEAE discontinuation, % (timing, yrs) (SD)

10.7 (0.95)

8.2 (0.71)

13.7 (1.22)

 Proportion other-cause discontinuation, % (timing, yrs) (SD)

20.1 (0.20)

16.0 (0.16)

24.9 (0.25)